Shalabh Singhal

658 total citations · 2 hit papers
34 papers, 463 citations indexed

About

Shalabh Singhal is a scholar working on Cardiology and Cardiovascular Medicine, Oncology and Rheumatology. According to data from OpenAlex, Shalabh Singhal has authored 34 papers receiving a total of 463 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Cardiology and Cardiovascular Medicine, 11 papers in Oncology and 10 papers in Rheumatology. Recurrent topics in Shalabh Singhal's work include Atrial Fibrillation Management and Outcomes (9 papers), Systemic Lupus Erythematosus Research (8 papers) and Cytokine Signaling Pathways and Interactions (8 papers). Shalabh Singhal is often cited by papers focused on Atrial Fibrillation Management and Outcomes (9 papers), Systemic Lupus Erythematosus Research (8 papers) and Cytokine Signaling Pathways and Interactions (8 papers). Shalabh Singhal collaborates with scholars based in United States, Netherlands and Germany. Shalabh Singhal's co-authors include Subhashis Banerjee, Alan Kivitz, Philip J. Mease, Miroslawa Nowak, Frank Behrens, Atul Deodhar, Ian M. Catlett, Désirée van der Heijde, Jeffrey Neal and Jonghyeon Kim and has published in prestigious journals such as New England Journal of Medicine, Circulation and SHILAP Revista de lepidopterología.

In The Last Decade

Shalabh Singhal

32 papers receiving 460 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II, Randomized, Double‐Blind, Placebo‐Controlled Trial

2022 139 citations Eric F. Morand, Marilyn C. Pike et al. Arthritis & Rheumatology profile →
Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis

2022 134 citations Philip J. Mease, Atul Deodhar et al. Annals of the Rheumatic Diseases profile →

Peers

Countries citing papers authored by Shalabh Singhal

Since Specialization

Citations

This map shows the geographic impact of Shalabh Singhal's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shalabh Singhal with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shalabh Singhal more than expected).

Fields of papers citing papers by Shalabh Singhal

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shalabh Singhal. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shalabh Singhal. The network helps show where Shalabh Singhal may publish in the future.

Co-authorship network of co-authors of Shalabh Singhal

This figure shows the co-authorship network connecting the top 25 collaborators of Shalabh Singhal. A scholar is included among the top collaborators of Shalabh Singhal based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shalabh Singhal. Shalabh Singhal is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Single Ascending-Dose Study of Selective ErbB4 Agonist JK07 in Heart Failure With Reduced Ejection Fraction 2025 ·JACC Basic to Translational Science ·Wen Tang, J. T. Steiner, (unknown), Matthew T. Wheeler, Aferdita Spahillari, Nancy K. Sweitzer, Justin L. Grodin, (unknown), Shalabh Singhal, (unknown), Samuel L. Murphy	0
2	Final Analysis Of Safety And Exploratory Echo Data In A Phase 1, First-in-human, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study To Evaluate JK07 In Subjects With Heart Failure With Reduced Ejection Fraction 2024 ·Journal of Cardiac Failure ·W.H. Wilson Tang, Johannes Steiner, Mahwash Kassi, Matthew T. Wheeler, Aferdita Spahillari, Nancy K. Sweitzer, Justin L. Grodin, Neal W. Salomon, Shalabh Singhal, (unknown), Samuel L. Murphy	1
3	Plain Language Summary of the PAISLEY study: deucravacitinib as a treatment for people with systemic lupus erythematosus 2024 ·Expert Opinion on Investigational Drugs ·Eric F. Morand, Marilyn C. Pike, Joan T. Merrill, Ronald van Vollenhoven, Victoria P. Werth, (unknown), Nikolay Delev, Vaishali Shah, Brian J. Sharkey, (unknown), Ian M. Catlett, Subhashis Banerjee, Shalabh Singhal	2
4	LP-187 Abstract withdrawn 2023 ·SHILAP Revista de lepidopterología ·Marta Mosca, Laurent Arnaud, Anca Askanase, (unknown), Shalabh Singhal, Subhashis Banerjee, (unknown), Jiyoon Choi, Adrian Coles, Brandon Becker, Vibeke Strand	1
5	Absolute and Relative Bioavailability of Oral Solid Dosage Formulations of Deucravacitinib in Humans 2023 ·Clinical Pharmacology in Drug Development ·Anjaneya Chimalakonda, Wenying Li, (unknown), Bing He, Shalabh Singhal, Prashant P. Deshpande, Jonathan Brown, (unknown), Bindu Murthy	2
6	POS0112 DEUCRAVACITINIB REDUCES INTERFERONS, B-CELL PATHWAYS, AND SEROLOGICAL BIOMARKERS OF SYSTEMIC LUPUS DISEASE ACTIVITY: PHARMACODYNAMIC ANALYSIS FROM THE PHASE 2 PAISLEY STUDY 2023 ·Annals of the Rheumatic Diseases ·J. Michelle Kahlenberg, Igñacio Sanz, Chun‐Ying Wu, Yanxin Hu, Ji Hong Kim, Shalabh Singhal, Ian M. Catlett	3
7	LSO-015 Deucravacitinib reduces interferons, B cell pathways, and serological biomarkers of systemic lupus disease activity: pharmacodynamic analysis from the phase 2 PAISLEY study 2023 ·SHILAP Revista de lepidopterología ·J. Michelle Kahlenberg, Igñacio Sanz, Chun‐Ying Wu, Yanhua Hu, Jin Hyang Kim, Shalabh Singhal, Ian M. Catlett	1
8	728 A phase 1/2 study of JK08, an IL-15 antibody fusion protein targeting CTLA-4, in patients with advanced solid tumors 2023 ·SHILAP Revista de lepidopterología ·Nuria Kotecki, Sylvie Rottey, (unknown), Elena Garralda, (unknown), Maria J. de Miguel, Omar Saavedra, Valentina Boni, (unknown), Shalabh Singhal, Samuel L. Murphy, Naimish Pandya	1
9	Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis breakdown → 2022 ·Annals of the Rheumatic Diseases ·Philip J. Mease, Atul Deodhar, Désirée van der Heijde, Frank Behrens, Alan Kivitz, Jeffrey Neal, Jonghyeon Kim, Shalabh Singhal, Miroslawa Nowak, Subhashis Banerjee	134
10	Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II, Randomized, Double‐Blind, Placebo‐Controlled Trial breakdown → 2022 ·Arthritis & Rheumatology ·Eric F. Morand, Marilyn C. Pike, Joan T. Merrill, Ronald van Vollenhoven, Victoria P. Werth, (unknown), Nikolay Delev, (unknown), Brian J. Sharkey, (unknown), Ian M. Catlett, Subhashis Banerjee, Shalabh Singhal	139
11	Population Pharmacokinetic Analysis of BMS‐986166, a Novel Selective Sphingosine‐1‐Phosphate‐1 Receptor Modulator, and Exposure‐Response Assessment of Lymphocyte Counts and Heart Rate in Healthy Participants 2020 ·Clinical Pharmacology in Drug Development ·(unknown), Shalabh Singhal, Diane E. Shevell, Huadong Sun, Jenny Xie, (unknown), (unknown), Santanu Dutta, Elizabeth Ludwig, Hannah Huang, (unknown), Aberra Fura, John Throup, Ihab Girgis	1
12	5 Oral selective tyrosine kinase 2 (TYK2) inhibition with BMS-986165 in patients with systemic lupus erythematosus: a phase 2, randomized, double-blind, placebo-controlled study (PAISLEY) 2019 ·Abstracts ·Shalabh Singhal, Vaishali Shah, (unknown), (unknown), (unknown), John Throup, Subhashis Banerjee, Joan T. Merrill	3
13	Treatment and discharge patterns among patients hospitalized with non-valvular atrial fibrillation transitioning from the inpatient to outpatient setting 2017 ·Current Medical Research and Opinion ·Henry J. Henk, Feng Cao, (unknown), (unknown), Prianka Singh, Jack Mardekian, (unknown), (unknown), (unknown), George H. Sands, Shalabh Singhal, Jeffrey Trocio, Lien Vo	1
14	REAL-WORLD COMPARISON OF MAJOR BLEEDING RISK AMONG UNTREATED NON-VALVULAR ATRIAL FIBRILLATION PATIENTS AND THOSE INITIATING APIXABAN, DABIGATRAN, RIVAROXABAN, OR WARFARIN 2016 ·Journal of the American College of Cardiology ·Alpesh Amin, Allison Keshishian, Lin Xie, Onur Başer, (unknown), Lien Vo, Jack Mardekian, (unknown), Shalabh Singhal, (unknown), (unknown), Jeffrey Trocio	2
15	Comparison of hospital length of stay between hospitalized non-valvular atrial fibrillation patients treated with either apixaban or warfarin 2015 ·Hospital Practice ·Amanda M. Farr, Yonghua Jing, Stephen S. Johnston, Jeffrey Trocio, Shalabh Singhal, Amanda Bruno, John Graham	13
16	Comparison of Short-Term Bleeding-Related Health Care Utilization and Costs Among Treatment-Naïve Nonvalvular Atrial Fibrillation Patients Initiating Apixaban, Dabigatran, Rivaroxaban, or Warfarin 2015 ·CHEST Journal ·Alpesh Amin, Allison Keshishian, Lin Xie, Onur Başer, (unknown), Lien Vo, Prianka Singh, Amanda Bruno, Jack Mardekian, (unknown), Shalabh Singhal, (unknown), (unknown), Jeffrey Trocio	2
17	Characteristics of Exercise‐Induced Intrapulmonary Arteriovenous Fistula in Patients with Unexplained Exertional Dyspnea 2010 ·Echocardiography ·(unknown), Shalabh Singhal, Jean Elwing, Yukitaka Shizukuda	3
18	Use of Bicycle Exercise Echocardiography for Unexplained Exertional Dyspnea 2009 ·Clinical Cardiology ·Shalabh Singhal, (unknown), Neal L. Weintraub, Yukitaka Shizukuda	5
19	Imaging of Thebesian Venous System 2008 ·New England Journal of Medicine ·Shalabh Singhal, Saeb F. Khoury	6
20	Risk of Major Bleeding with Concomitant Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients Receiving Long‐Term Warfarin Therapy 2007 ·Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy ·(unknown), Louis Kolman, Matthew DeCaro, Jocelyn Andrel, Inna Chervoneva, (unknown), Linh Lam, Christopher McGowan, Grace M. Lee, (unknown), Nicholas Ruggiero, Shalabh Singhal, Arnold J. Greenspon	77

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact